Portal hypertension and ascites in systemic mastocytosis

M.N. Narayanan, J.A. Liu Yin, S. Azzawi, T.W. Warnes¹ and W.P.G. Turck²

Department of Clinical Haematology and ¹Gastroenterology, The Royal Infirmary, Manchester and ²Department of Medicine, Bury General Hospital, Bury, UK.

Summary: We report a case of systemic mastocytosis (SM) presenting as ascites and portal hypertension. The haematological picture at presentation was suggestive of chronic myelomonocytic leukaemia. Initial difficulties in making a diagnosis of SM were encountered as the cutaneous signs were atypical. The correct diagnosis was established only after tissue sections were appropriately stained for mast cells. The liver biopsy showed portal and sinusoidal mast cell infiltration, portal fibrosis and evidence of hepatic venous outflow obstruction. The disease progressed rapidly and recurrent massive ascites was a dominant problem. This case illustrates again the problems of making a diagnosis of SM especially when the clinical picture is atypical. Ascites as a presenting manifestation of SM has been reported previously in only six patients. Published cases of SM with portal hypertension or ascites or both are reviewed.

Introduction

Systemic mastocytosis (SM) is a rare disease characterized by the proliferation of mast cells in skin, bones, lymph nodes and parenchymal organs.¹² The cutaneous form, urticaria pigmentosa, is the most common mastocytosis. Portal hypertension and ascites are rare manifestations of SM.⁴⁻⁹ (Table I). A review of English language publications revealed that ascites as a presenting feature of SM has been reported in only 6 patients.⁴⁻⁹ We describe a patient with SM who presented with ascites and discuss the problems of making a correct diagnosis in the absence of typical cutaneous signs.

Case report

A previously well 49 year old male presented with a 6-week history of cough, general weakness and night sweats. Clinical examination showed pallor, low grade pyrexia, a punctate erythematous rash around the neck, ascites and hepatomegaly. Investigations showed: haemoglobin 11.1 g/dl, white cell count 11.3 x 10⁹/l (neutrophils 59%, lymphocytes 14%, monocytes 19%, myelocytes 8%), platelets 77 x 10⁹/l, ESR 50 mm/h. Liver function tests demonstrated hepatocellular impairment with a serum albumin varying from 27–32 g/l and a prolonged prothrombin time at 19 seconds (control 14 seconds); serum alkaline phosphatase was also raised at 56 KA U/dl (liver origin on isoenzyme fractionation). Computed tomographic scan of the abdomen showed hepatosplenomegaly and a possible mass anterior to the left kidney; the appearances were suggestive of lymphoma. Ascitic fluid protein content was 41 g/l; on cytology serosal cells and macrophages but no malignant cells were seen.

At laparotomy 10 litres of straw coloured fluid were obtained but there was no evidence of intra-abdominal malignancy. The liver felt cirrhotic and the spleen was enlarged. The liver biopsy showed periportal fibrosis with mild inflammatory cell infiltration, extramedullary haemopoiesis with cellular infiltrate in the sinusoids suggestive of myeloid leukaemia, and centrilobular cell loss and congestion consistent with hepatic venous outflow obstruction. Postoperatively the ascites recurred.

There was no evidence of varices on endoscopy. Isotope liver scan showed nonspecific changes. Skeletal survey showed generalized bony sclerosis. Hepatic vein catheterization via the antecubital route showed patent hepatic veins with a raised (corrected) wedge hepatic vein pressure (17 mmHg), consistent with a sinusoidal or postsinusoidal type of portal hypertension. Mild anaemia persisted and the white cell count rose to 20 x 10⁹/l, with a monocyte count of 2 x 10⁹/l. Serum lysozyme was raised at 34 mg/l. The bone marrow was markedly hypercellular with hyperplasia of the granulocytic series and excess of monocytes; karyotypic examination was normal. A tentative diagnosis of chronic myelomonocytic leukaemia was made.

However, subsequent histological review of the liver biopsy stained with toluidine blue (Prof P. Scheuer,
Table I Portal hypertension and ascites in systemic mastocytosis

<table>
<thead>
<tr>
<th>References</th>
<th>Ascites at diagnosis</th>
<th>Ascites years after diagnosis</th>
<th>PH</th>
<th>Age/ Sex</th>
<th>Mechanism of ascites</th>
<th>Mechanism of PH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zak (1957)3</td>
<td>no</td>
<td>yes</td>
<td>unknown</td>
<td>58F</td>
<td>unknown</td>
<td>NA</td>
</tr>
<tr>
<td>Bloom (1960)4</td>
<td>yes</td>
<td>NA</td>
<td>unknown</td>
<td>47F</td>
<td>MCI</td>
<td>NA</td>
</tr>
<tr>
<td>Capron (1978)5</td>
<td>no</td>
<td>no</td>
<td>yes</td>
<td>66M</td>
<td>NA</td>
<td>tPF + MCI</td>
</tr>
<tr>
<td>Grundfest (1980)6</td>
<td>no</td>
<td>yes</td>
<td>yes</td>
<td>55M</td>
<td>NA</td>
<td>SBF</td>
</tr>
<tr>
<td>Sawers (1982)7</td>
<td>no</td>
<td>yes</td>
<td>yes</td>
<td>51M</td>
<td>PH + HCDF</td>
<td>MCI</td>
</tr>
<tr>
<td>Ghandur-Mnaymneth (1985)8</td>
<td>yes</td>
<td>NA</td>
<td>yes</td>
<td>51M</td>
<td>PH + HCDF</td>
<td>MCI + SECD</td>
</tr>
<tr>
<td>Yam (1986)9</td>
<td>4†</td>
<td>1†</td>
<td>ND</td>
<td>ND*</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Narayanan (current study)</td>
<td>yes</td>
<td>NA</td>
<td>yes</td>
<td>49M</td>
<td>PH + HCDF</td>
<td>MCI + HVOB</td>
</tr>
</tbody>
</table>

NA, not applicable; PF, portal fibrosis; MCI, mast cell infiltration; SBF, splenic blood flow; PH, portal hypertension; HCDF, hepatocellular dysfunction; SECD, subendothelial collagen deposition; ND, no details of individual patients available; * one patient had diffuse involvement by mast cells of peritoneum and omentum; † number of patients; HVOB, hepatic venous outflow block.

Royal Free Hospital) showed significant mast cell infiltration in the portal tracts. The diagnosis of SM was confirmed by the demonstration of mast cell infiltration in the bone marrow trephine biopsy, splenunculus (removed at laparotomy) and skin biopsy.

Initially the patient’s ascites responded to medical management consisting of abdominal paracentesis and chemotherapy with 6-mercaptopurine and hydroxyurea. Subsequently the ascites recurred and proved very resistant to therapeutic intervention. Eventually the patient developed cachexia, intractable ascites and peptic ulceration and died of bronchopneumonia, 8 months after the diagnosis was made.

Autopsy showed bronchopneumonia, ascites and duodenal ulcers with old perforation. The spleen showed mast cell infiltration, multiple infarcts and residual fibrosis. The liver showed centrifibular necrosis, expanded portal tracts and bile ductule proliferation. The lymph nodes showed extensive infiltration by mast cells.

Discussion

Hepatic involvement is common in SM. Asymptomatic hepatomegaly was present in 10 out of 13 cases in one series.9 Mast cell infiltration of the liver was present in all 13 cases in one report8 and in 14 out of 17 cases in another.1 Results of liver function tests are variable but serum alkaline phosphatase was elevated in all 13 patients in one report.5

Portal hypertension in SM was first reported in 1978.2 Since then 3 more cases of SM with portal hypertension have been described6–8 (Table I). In 3 other cases of SM with ascites, it is uncertain whether portal hypertension was present or not.3,4,9

The portal hypertension was thought to be due to increased splenic blood flow in one case where the portal pressure returned to normal following splenectomy. Increased splenic blood flow was thought to be a contributory factor in another case.9 Presinusoidal and sinusoidal block due to mast cell infiltration and resulting fibrosis was thought to be the main mechanism of portal hypertension in 3 cases.5,7,8

Subendothelial collagen deposition was demonstrated in hepatic sinusoids at electron microscopy in one case.8 In our case there was portal and sinusoidal mast cell infiltration and fibrosis. In addition there was evidence of hepatic venous outflow block occurring in the small hepatic vein radicles presumably due to MC infiltration and fibrosis. It may be that the mechanisms of portal hypertension in SM are not necessarily the same in all cases.

Zak1 reported a case of SM where the patient developed ascites during the course of the illness. Since then 8 more cases of SM with ascites have been reported4–9 six of these presented with ascites4,8,9 and 2 developed ascites during the course of their disease.7,9 Two patients had diffuse infiltration of peritoneum and omentum by mast cells5,9 which was thought to be directly responsible for the ascites. A combination of hepatocellular dysfunction together with portal hypertension was thought to be the mechanism of ascites in 3 cases including ours. The mechanisms involved are uncertain in 2 other cases.3,9 The salient features of these cases are summarized in Table I.

Difficulty in diagnosing SM in the absence of urticaria pigmentosa is well known.10 In our patient the skin rash was atypical and therefore overlooked. The other diagnoses considered at presentation were chronic myeloid leukaemia, lymphoma and car-

Downloaded from http://pmj.bmj.com/ on October 20, 2017 - Published by group.bmj.com
cinomatosis. The anaemia, blood and marrow mononcytosis, granulocytic hyperplasia and high serum lysozyme level suggested a diagnosis of chronic myelomonocytic leukaemia.11,12 Seventeen percent of patients with SM in one series10 had monocyctosis and granulocytic hyperplasia was found frequently in bone marrow aspirates. Three cases in another series of SM were diagnosed as myelomonocytic leukaemia based on haematological and clinical findings.13 One case7 was diagnosed as myelofibrosis initially and the true diagnosis of SM was made only 10 years later from liver and bone marrow biopsies. Differentiation of SM from other myeloproliferative disorders depends on the demonstration of mast cell infiltration in bone marrow or other organs using appropriate cyto-chemical techniques and aided by a high index of suspicion.

Although ascites was a dominant feature in our patient, the eventual deterioration and death were due to the general effects of cachexia, peptic ulceration, perforation and sepsis. This is consistent with the observation7 that the prognosis in SM is related to the systemic effects of mast cell involvement in many organs.

Acknowledgements

The authors thank Prof P.J. Scheuer and Dr N.Y. Haboubi for their help in establishing the diagnosis.

References
